Effective Reprogramming Strategies for Treating Diabetes-Related Cancer: A Focus on Fasentin, Metformin, and Panitumumab Therapies

Abstract

Cancer is a condition characterized by the uncontrolled growth and spreading of certain cells within the body. The formation of malignant tumors necessitates a substantial amount of energy to sustain the abnormal rate of cell division. This process leads to a significant alteration in the primary metabolic pathway, transitioning from mitochondrial respiration to aerobic glycolysis, particularly in cancers associated with diabetes. This shift creates an opportunity for less invasive treatment options that can limit cancer growth by targeting specific transporters and enzymes crucial for energy production. This article focuses on the biological functions of Fasentin and Metformin, exploring their effectiveness in constraining cancer development. The discussion delves into their roles in regulating metabolism and highlights how these drugs can be instrumental in impeding the progression of cancer.